MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons
- PMID: 38697112
- DOI: 10.1016/j.neuron.2024.04.007
MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons
Abstract
Mutations in the methyl-DNA-binding protein MECP2 cause the neurodevelopmental disorder Rett syndrome (RTT). How MECP2 contributes to transcriptional regulation in normal and disease states is unresolved; it has been reported to be an activator and a repressor. We describe here the first integrated CUT&Tag, transcriptome, and proteome analyses using human neurons with wild-type (WT) and mutant MECP2 molecules. MECP2 occupies CpG-rich promoter-proximal regions in over four thousand genes in human neurons, including a plethora of autism risk genes, together with RNA polymerase II (RNA Pol II). MECP2 directly interacts with RNA Pol II, and genes occupied by both proteins showed reduced expression in neurons with MECP2 patient mutations. We conclude that MECP2 acts as a positive cofactor for RNA Pol II gene expression at many neuronal genes that harbor CpG islands in promoter-proximal regions and that RTT is due, in part, to the loss of gene activity of these genes in neurons.
Keywords: MECP2; RNA polymerase II; Rett syndrome; chromatin binding; transcriptional regulation.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests R.J. is an advisor and co-founder of Fate Therapeutics and Fulcrum Therapeutics. A.F. is a co-founder and shareholder of StemAxon. R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics, Dewpoint Therapeutics, and Paratus Sciences.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials